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ABSTRACT
With the intent to identify biomarkers in renal cell carcinoma (RCC) the functional 
status of T-regulatory cells (Tregs) was investigated in primary RCC. Tregs were 
isolated from tumoral-(TT), peritumoral tissue-(PT) and peripheral blood-(PB) 
of 42 primary RCC patients and function evaluated through effector T cells (Teff) 
proliferation, cytokines release and demethylation of Treg Specific Region (TSDR). 
The highest value of Tregs was detected in TT with the uppermost amount of 
effector-Tregs-(CD4+CD25hiFOXP3hiCD45RA-). PB-RCC Tregs efficiently suppress 
Teff proliferation compared to healthy donor (HD)-Tregs and, at the intrapatient 
evaluation, TT-derived Tregs were the most suppressive. Higher demethylation TSDR 
was detected in TT- and PB-RCC Tregs vs HD-Tregs (P <0,001). CXCR4 is highly 
expressed on Tregs, thus we wished to modulate Tregs function through CXCR4 
inhibition. CXCR4 antagonism, elicited by a new peptidic antagonist, Peptide-R29, 
efficiently reversed Tregs suppression of Teff proliferation. Thus Tregs functional 
evaluation precisely reflects Tregs status and may be a reliable biomarker of tumoral 
immune response. In addition, treatment with CXCR4 antagonist, impairing Tregs 
function, could improve the anticancer immune response, in combination with 
conventional therapy and/or immunotherapy such as checkpoints inhibitors.
INTRODUCTION
Renal cell carcinomas (RCCs) is a disease with 
an estimated 338,000 new cases diagnosed worldwide 
[1] with approximately 30% of patients presenting with 
metastatic disease. High-dose IL-2 and Interferon-α 
were the principal therapies for metastatic RCC; due to 
the harsh-tolerance profiles and limited response rates, 
immunotherapies were replaced with targeted therapies 
but only everolimus has an impact on overall survival 
(NCCN guidelines Version 2.2016). The human IgG4 
anti-PD-1 monoclonal antibody, Nivolumab, was recently 
approved to treat advanced (metastatic) clear cell renal 
cell carcinoma (ccRCC) patients who have received a 
prior anti-angiogenic therapy [2] resulting in 30% of 
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clinical response. Immunotherapy efficacy is controlled 
by multiple mechanisms such as the recruitment of 
immunosuppressive cells to the tumor microenvironment 
(Tregs, Myeloid derived suppressor cells-MDSCs) [3]. 
T regulatory cells (Tregs) suppress a whole range of 
immune cells including B cells, NK cells, NKT cells, 
CD4+ or CD8+ T cells, monocytes and dendritic cells [4]. 
Nevertheless, Tregs role in cancer microenvironment is 
controversial: Tregs are associated with poor prognosis 
in renal [5], ovarian [6], pancreatic [7] and liver cancer 
[8], while others showed no correlation between tumor-
infiltrating Tregs and patient outcome [9]. Tregs are 
identified through the surface expression of CD3, CD4, 
CD25, FOXP3, CD127 and CD45RA. In addition ICOS, 
a member of CD28/CTLA-4 family and CD39/ENTPD1 
defines a highly suppressive Treg population [10]. CTLA-
4 and PD-1 have also been proposed as key molecules 
in generation and/or suppressive function of Tregs [11]. 
Cancer patients derived Tregs usually express a distinct 
profile of chemokine receptors, such as CCR4, CXCR4 
and CCR5, which facilitates their migration into tumors in 
response to the corresponding chemokine ligands derived 
from tumor microenvironment [12]. With the intent to 
characterize the local antitumor immune response Tregs 
were functionally evaluated in 42 RCC patients. Moreover, 
CXCR4 antagonism was investigated as a strategy to 
impair Treg efficiency.
RESULTS
Tregs isolated from primary tumor (TT), 
peritumoral tissue (PT) and peripheral blood 
(PB) of renal cancer (RCC) patients are highly 
activated
Tregs, identified as percentage of CD4+CD25hiFOXP3+ 
cells, were evaluated in 42 consecutive renal cancer patients 
(Table 1). A significantly higher number of Tregs was 
detected in 42 RCC-PB as compared to 15 healthy donors 
(HD) (Figure 1Ai) Intrapatients analysis demonstrated 
higher Tregs in TT versus PT and PB. In Figure 1B a 
representative plot of HD-Tregs and RCC-Tregs was shown. 
As shown in Figure 1C-1D, TT-Tregs displayed the highest 
level of CTLA-4, ICOS, ENTPD1, CD45RA, PD-1 and 
CXCR4. According to the Tregs functional classification 
that distinguish CD25hiFOXP3hiCD45RA- as effector and 
CD25hiFOXP3lowCD45RA- as not suppressive Tregs [13], 
the highest number of effector Tregs was detected in TT 
(PB and PT vs TT, P <0,001) (Figure 2A); in Figure 2B a 
representative analysis of Tregs subpopulations is shown 
(PB/PT/TT). PB-Tregs from RCC patients cocultured 
with autologous Teff cells more efficiently suppress Teff 
proliferation compared to HD-Tregs (Figure 3A-3B). In 
Figure 3C a representative analysis of CFSE-labeled Teff 
proliferation-Treg dependent was shown. As control, anti-
CD3/CD28-stimulated CD4+CD25+ T cells were anergic 
while Teff intensively proliferated (Supplementary Figure 1).
TT-Tregs are more suppressive than PB- and PT- 
Tregs in RCC patients
In Figure 4A, TT-, PT- and PB- isolated Tregs 
significantly suppressed autologous Teff cells proliferation 
(P <0,001). In particular, TT-Tregs more efficiently 
suppressed T-effector proliferation compared to PT- and 
PB-Tregs (Figure 4A). In Figure 4B a representative 
suppression assay was shown. Treg function is also 
regulated through the status of methylation of Treg-
specific demethylated region (TSDR). Thus FOXP3-
TSDR demethylation status was investigated on TT- and 
PB-Tregs from RCC patients and compared to HD. High 
demethylation rate was detected in TT-RCC and PB-
RCC vs HD derived Treg cells (P <0,001) (Figure 5A). 
As reference sequence the methylation of CpG sequences 
of IFN transcription regulatory factors 8 (IRF8) was 
considered [14, 15]. Moreover to evaluate Tregs function 
culture supernatants were evaluated for IFN-γ and TGF-β1 
on day 5 of cocolture. As shown in Figure 5B, a significant 
decrease of IFN-γ was observed when TT-Tregs were 
added to autologous Teff cells. Of interest, very low 
Table 1: Clinical characteristics of RCC patients
No. of patients 42
Median age (range), yr 59 (28-83)
Gender (Female/Male) 14/28
Pathological stage (pT1/pT2/pT3/pT4/missing) 27/4/9/1/1
Tumor size cm( >5/≤5/missing) 14/27/1
Histologic variant
(clear cell/papillary/chromophobe/papillary-
clear cell/mucinous tubular and spindle cell)
31/4/2/4/1
Furhman’s grade (1/2/3/missing) 3/11/23/5
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Figure 1: High CD4+CD25hiFoxp3+ Tregs in RCC tumors. (Ai) Percentage of CD4+CD25hiFoxp3+ (15 HD vs 42 PB p<0.001; HD 
vs 42 peritumoral P <0.05; HD vs 42 tumor P <0.001) (tumor vs peritumoral P <0.001; tumor vs PB P <0.001). (Aii) Absolute number 
of CD4+ in 15 HD, 42 peripheral and (Aiii) 42 tumor/peritumor tissue. (B) Representative example in HD (#12) (absolute CD4+/μl: 722) 
and RCC patients (# 39) (absolute CD4+/μl in PB:733; absolute CD4+/100 mg tissue: peritumoral 850 vs tumoral 2600). (C) Percentage 
of CTLA-4, PD1, CXCR4 ICOS, ENTPD1 and CD45RA, in CD4+CD25hiFoxp3+ cells. (D) Representative plots of Tregs from HD (#12) 
and RCC-PB, -PT and -TT patient (#39).
Figure 2: Higher CD25hiFoxp3hiCD45RA- effector Tregs in RCC tumors. (A) Phenotypic characterization of naïve, effector and 
not suppressive Tregs in 34 RCC patients (PB and PT vs TT, P <0,001). (B) Representative analysis of Tregs subpopulations (patient #21).
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IFN-γ production was observed in cultures with PB-Tregs. 
Surprisingly, a dramatic increase in IFN-γ was observed 
in coculture of PT-Tregs. This increase could be ascribed 
to IFN-γ production from tumor infiltrating lymphocytes 
(TIL) that induce inhibitory T cell ligands such as PD-L1 
[16]. As expected, a significant increase of TGF-β1 was 
observed when TT-Tregs were added to autologous Teff 
cells (Figure 5C). TGF-β1 and IL-10 mRNA expression 
was also evaluated in TT and PT RCC tissues. Consistent 
with an increased Treg function, TGF-β1 expression, 
though not significant, increased in tumoral tissues (PT 
vs TT: 0.06±0.08 vs 0.20±0.30) while IL-10 expression 
dramatically increased in TT as compared to PT samples 
(tumoral vs peritumoral: 0.36±0.37 vs 0.08±0.14, p<0,01) 
(Supplementary Figure 2). Altogether these data suggest 
that, although TT-Tregs share some phenotypic similarities 
with both PT- and PB-Tregs, they are functionally more 
suppressive.
CXCR4 antagonists impair RCC-tregs function
Since CXCR4 is highly expressed by Tregs, we 
speculate that interfering with CXCR4 signaling might 
inhibit the Tregs suppressive function. A new family of 
CXCR4 antagonists was recently developed by us [17]. In 
Figure 6A the effect of the canonical CXCR4 antagonist 
AMD3100 and the new Peptide R29, was evaluated 
[17, 18]; when PB-Tregs were pretreated with CXCR4 
antagonists and then added to coculture with Teff, an 
efficient reversal of Treg suppressive CSFE proliferation 
was detected (1:1 vs 1:1+ Peptide R29: 5±5% vs 57±39%; 
1:1 vs 1:1+AMD3100: 5±5% vs 58±5%). As positive 
control, pretreatment of Tregs with anti-PD1 reverted 
PB-RCC derived Treg suppression of Teff proliferation 
at a comparable extent of Peptide R29 (Figure 6A). In 
Figure 6B a representative example of reversal of Treg 
suppressive capability was shown. Treatment of Teff with 
AMD3100 or R29, in absence of Tregs, did not affect 
proliferation (Supplementary Figure 3A and 3B). No 
significant effect of CXCR4 antagonism was observed 
on Teff proliferation in presence of HD isolated Tregs 
(Supplementary Figure 3C). Comparable results were 
obtained from TT isolated Tregs (data not shown). To 
exclude a toxic effect of CXCR4 antagonist on Tregs, 
viability was evaluated on Tregs pretreated with Pep R29 
through the 7-AAD exclusion test; as shown in Figure 
Figure 3: PB-Tregs from RCC patients are more suppressive than HD-Tregs. (A-B) AutologousCFSE-labeledCD4+CD25- 
T cells were co-cultured with CD4+CD25+ isolated from peripheral blood of 6 HD and 8 RCC patients (at the Teff:Treg ratios from 1:1 
to 1:0.007; the 1:0 ratio indicated the positive control). After 5 days of stimulation with Dynabeads Human T-Activator CD3/CD28, 
CFSE+CD4+ T cells were analyzed for their proliferation by CFSE dilution. (C) Representative analysis of CFSE-labeled Teff proliferation 
of HD (#8) and RCC (#12) patient in the presence of Tregs.
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Figure 4: TT-Tregs are more suppressive than PB and PT-Tregs in RCC patients. (A) AutologousCFSE-labeled CD4+CD25- 
T cells were co-cultured with CD4+CD25+ isolated from peripheral blood (PB), tumor (TT) and peritumoral (PT) of 19 RCC patients as 
indicated. Histograms show the results relatively to 19 RCC patients. (B) Representative FACS analysis of suppression assay with PB-Tregs 
RCC isolated Tregs in one RCC patient (#8).
Figure 5: TT-Tregs are more suppressive than PB and PT-Tregs in RCC patients. (A) Demethylation rate of FOXP3-TSDR 
in TT-Tregs and PB-Tregs versus HD-Tregs (2 TT-Tregs vs 4 PB-Tregs vs 3 HD respectively). (B) IFN-γ-Treg dependent ELISA and (C) 
TGF-β1-Treg dependent ELISA from 8 RCC patients.
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6Ci-6Cii, when PB-Tregs were incubated with Pep R29 
viability was unaffected. Moreover, a significant increase 
of IFN-γ was observed when PB-Tregs were pretreated 
with Pep R29, AMD3100 and anti-PD1 and then added 
to autologous Teff cells (1:1 vs 1:1+ Peptide R29: 1±2 vs 
99±53; 1:1 vs 1:1+AMD3100: 1±2 vs 108±36; 1:1 vs 1:1+ 
anti-PD1: 1±2 vs 70±45) (Figure 6D) suggesting a recover 
in T-effector proliferative activity. As control, supernatant 
from isolated Teff plus and minus Dynabeads Human 
T-Activator CD3/CD28 were evaluated for the IFN-γ 
secretion (Supplementary Figure 4).
DISCUSSION
Tumors actively escape the immune system through 
complex mechanisms including inhibitory receptors, 
secreted soluble inhibitors (IL-10 and TGF-β) and Tregs 
[19]. In the present study Tregs were evaluated in 42 RCC 
patients: higher number of Tregs was detected in tumoral 
tissue as compared to peritumoral and peripheral Tregs 
as previously described in patients with head and neck 
squamous cell carcinoma, breast, pancreatic, stomach 
and liver cancer [20]. In here, Tregs expressing CTLA-4, 
ICOS, ENTPD1, CD45RA and PD-1 were the majority 
among tumoral Tregs and the so called effector Tregs, 
CD25hiFOXP3hiCD45RA- highly suppressive cells, were 
the most represented among tumor Tregs tissue derived 
[13]. Higher number of intratumoral Tregs with activated 
phenotype was previously reported in non-small-cell 
lung cancer patients and rectal cancer [21]. The elevated 
number of Tregs in RCC environment raises the question 
of their immunosuppressive capability. We found that 
tumoral Tregs display higher immunosuppressive 
activity compared to peritumoral and peripheral Tregs 
as demonstrated by reduced Teff proliferation and IFN-γ 
production. The high IFN-γ production in the cocolture of 
peritumoral Treg and T effectors can probably be ascribed 
to IFN-γ production from TIL cells that induce inhibitory 
T cell ligands such as PD-L1 [16]. Moreover, high Treg 
activity was supported by TGF-β production in culture 
supernatants [10]. These data suggest that functional Tregs 
accumulated in the RCC tumors control tumor immunity. 
Figure 6: CXCR4 antagonists reverses the suppressive capability of Tregs from RCC patients. (A) CFSE-labeledCD4+CD25- 
T cells were co-cultured at the 1:1 Teff:Treg ratio with CD4+CD25+ PB Tregs from 6 RCC patients. Tregs were pretreated for 30’ at 37°C in 
5% CO2 with R29 (10 μM), AMD3100 (10 μM) or anti-PD1 (20 μg/mL) and then added to the Teff cells for 5 days. Teff cells were analyzed 
for their proliferation by CFSE dilution. (B) Representative effect of CXCR4 antagonists (R29, AMD3100) or anti-PD1 on Teff-CSFE 
proliferation-Treg mediated in RCC patients (#41). (Ci) Viability of isolated Tregs from 3 RCC patients pretreated for 30’ at 37°C in 5% 
CO2 with R29 (10 μM) washed and then stained with 7-AAD. (Cii) Rapresentative analysis of 7-AAD staining in Tregs isolated from one 
RCC patients. (D) IFN-γ-Treg dependent production through ELISA from 6 RCC patients with Tregs pretreated for 30’ at 37°C in 5% CO2 
in presence of R29 (10 μM), AMD3100 (10 μM) or anti-PD1 (20 μg/mL).
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Tregs function is regulated through methylation of Treg-
specific demethylated region (TSDR). TSDR is a CpG 
dinucleotide rich domain and highly conserved region 
within the conserved non coding sequences 2 (CNS2), 
located in the first intron of FOXP3 gene [22]. TSDR-
hypermetilated Tregs impaired suppressive function 
[23]; recent evidence demonstrated TSDR demethylation 
in liver biopsy and peripheral blood samples from 
patients with advanced grades of HCC compared to 
control subjects with nonmalignant disease [24]. Herein 
we show that TSDR demethylation increases in RCC 
isolated Tregs suggesting a higher suppressive function 
compared to healthy donors isolated Tregs. These results 
were compared to the demethylation induced by DNMTi 
azacytidine (AZA) and IFN-γ on unrelated sequence in 
the promoter of the Interferon Regulated Factor IRF-8 
[14, 15]. Tregs from RCC patients express higher CXCR4 
compared with Tregs from healthy donors. CXCR4 
receptor is activated by the ligand CXCL12 that regulates 
T cell access and recruits immunosuppressive population 
to tumoral microenvironment including interleukin-10–
producing plasmacytoid dendritic cells, Tregs and 
MDSCs. In a mouse model of ovarian cancer the CXCR4 
antagonist, AMD3100, determined several anti-tumor 
effects including increased tumor cell death, reduced 
dissemination and better survival of the treated animals. 
Significantly, it was observed a selective reduction in the 
recruitment of Foxp3+ T cells in comparison with CD8+ T 
cells [25]. Blockade of both CXCR4 and PD-1 prevents 
suppression of immune cell function in HCC tumors, 
enhances immune cell tumor penetration and activation, 
and ultimately delays HCC progression [26]. In our 
experience CXCR4 antagonism with AMD3100 or with 
a new class of CXCR4 antagonists (Peptide R29) reverts 
Treg suppressive function in RCC patients. CXCR4 
transduction may regulate some genes critical in Treg 
function since CXCL12/CXCR4 signaling plays a key role 
in human thymocyte development, promoting survival and 
expansion of human early T-cell progenitors [27].
The mechanism through which CXCR4 antagonists 
impact on Treg function is under evaluation. A possibility 
is that CXCR4 transduction impairs the methylation 
status of FOXP3. In metastatic renal carcinoma IL-2 
based immunotherapy leads to substantial expansion of 
T-cells with a demethylated TSDR. Preliminary evidence 
displayed a reduced demethylation in TSDR when RCC 
derived Tregs were treated with CXCR4 antagonists 
(Santagata et al, manuscript in preparation). Post 
translational modification such as acetylation can regulate 
Treg-FOXP3 activity [28]. Because CXCR4 signaling 
transduces also on FOXP3 and HDACis upregulated 
CXCR4 mRNA expression [29], it is possible that CXCR4 
modulation affects the acetylation status of FOXP3 gene 
promoter.
Although the anti PD-1 Nivolumab was recently 
approved to treat advanced (metastatic) clear cell renal 
cell carcinoma (ccRCC), only a minority of patients 
display a durable anti PD-1 response. This effect might be 
due to the tumor microenvironment lacking the efficient 
T-effector cells access to tumors and to a recruitment 
of immunosuppressive cells. Targeting the CXCR4-
CXCL12 axis could revert the tolerogenic polarization of 
the microenvironment rich of immunosuppressive cells 
such as Tregs cells M2 and N2 neutrophils [25, 30, 26], 
improving immunotherapeutic intervention in patient with 
RCC. Preliminary evidence from an ongoing observational 
trial demonstrates that Tregs functional status in peripheral 
blood of nivolumab treated metastatic renal cancer patients 
is predictive of drug sensitivity [31]. Although the number 
of Tregs isolated from peripheral blood was adequate to 
functionally evaluate the role of Tregs in RCC patients, the 
Tregs isolated from primary tumors was a limiting factor. 
Moreover the interpatients variability required an adequate 
number of patients to draw conclusions. In conclusion 
RCC patients at peripheral, tumor and peritumoral sites, 
contain high numbers of functional Tregs and intratumoral 
Tregs actively limits the tumoral immune response. 
Thus monitoring Treg function also in peripheral blood 
could be informative on the antitumor immune response 
and possibly predictive of immunotherapy response. 
Moreover, CXCR4 antagonism is able to reverse in 
vitro Tregs suppressive capability on effector T cells 
proliferation suggesting that targeting CXCR4 may 
improve immunotherapy in RCC.
MATERIALS AND METHODS
Patients and specimens
RCC samples were collected from 42 RCC patients 
undergone partial/radical nephrectomy at the Urology Unit 
of Istituto Nazionale per lo Studio e la Cura dei Tumori, 
Fondazione “G. Pascale” and Genitourinary Oncology 
and Rare Cancer Center, Federico II University in Naples. 
Renal tumor (TT) and peritumoral tissue (PT) specimens 
were collected at the time of surgery.
The distance 1cm was the minimal distance between 
tumor and normal-appearing renal tissue sampled (PT). In 
addition, 8-mL of heparinized peripheral blood (PB) was 
collected from each patient before surgery. Heparinized 
blood was also collected from 15 healthy donors (HD). 
Patients features are shown in Table 1. The research 
protocol was approved by Human Ethical Committee of 
Institute (n. CEI/423/13).
Cells preparation
Peripheral blood samples from cancer patients and 
healthy donors were drawn into heparinized tubes (BD 
Biosciences) and centrifuged on Ficoll–Hypaque gradients 
(GE Healthcare Bioscience). For tissue-infiltrating 
lymphocytes isolation, freshly isolated tumors sample 
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and corresponding peritumoral renal tissue biopsies 
were minced into small pieces, digested with 1 mg/mL 
of collagenase (Sigma-Aldrich) for 30 minutes at 37°C, 
then transferred to a cell strainer (70μm Nylon) (BD 
Biosciences) and gently separated by using a syringe 
plunge. The collected cells underwent to Ficoll–Hypaque 
gradient centrifugation, washed and immediately used for 
experiments.
Antibodies and flow cytometric analysis
Flow cytometry was performed on venous peripheral 
blood collected in heparin-coated vacutainer tubes, on 
tumor and peritumoral tissues using a FACSCanto II 
6-colour flow cytometer, daily calibrated with calibrite 
beads (Fitc, Pe, PerCP and APC) and compbeads (Pe-
Cy7 and APC-Cy7; Becton Dickinson, San Jose, CA, 
USA). Fluorochrome-labelled monoclonal antibodies (BD 
Bioscience) for identification of circulating and tissue Treg 
cells were used: Fitc-anti-FOXP3, Pe-Cy7-anti-CD25, 
APC-Cy7-anti-CD4, APC-anti-CD45RA, Pe-anti-CD152 
(CTLA-4), PercP-anti-CD184 (CXCR4), APC-anti-CD279 
(PD-1), Pe-anti-CD278 (ICOS) and APC-anti-CD39 
(ENTPD1). Intracellular staining for FoxP3, ICOS and 
CTLA-4 was performed using a commercially available 
kit (BD Cytofix/Cytoperm; fixation and permeabilization 
kit; BD Pharmingen) according to the manufacturer’s 
instructions. A minimum of 100.000 events for each 
sample were collected and data were analysed using 
FacsDiva software 6.1.3 (BD Bioscience). The absolute 
number of CD4 was calculated as follow: [total withe 
blood cell count (cells/uL) x percent CD4]/100 or [total 
tumor-infiltrating immune cell count (cells/100 mg tumor) 
x percent CD4]/100.
Purification of T cell subsets
Peripheral, tumor and peritumoral CD4+CD25+ 
Tregs and peripheral CD4+CD25− T effector (Teff) 
cells were isolated using the Dynabeads Regulatory 
CD4+CD25+ T cell kit. Briefly, CD4+ cells were separated 
by negative selection, using the antibody mix human CD4. 
In the second step, a depletion beads solution was added 
to remove the non-CD4 cells. Then, CD25-beads was 
added to CD4+ T cells to capture the CD4+CD25+ Tregs 
and the remaining fraction was used as CD4+CD25− Teff 
cells. Finally, Dynabeads CD25 was removed from the 
cells. All purification steps were performed according 
to the manufacturer’s instructions (Invitrogen by Life 
Technologies) and collected cells were found to be > 95% 
pure by flow cytometry.
Suppression assay
Carboxyfluorescein diacetate succinimidyl ester 
(CFSE)-labeled autologous CD4+CD25− T cells from 
peripheral blood (CellTrace CFSE Cell Proliferation Kit, 
Molecular Probes, by Life Technologies) were cultured 
with peripheral CD4+CD25+ Tregs at different ratios (1:1, 
1:0.5, 1:0.25, 1:0.125, 1:0.06, 1:0.03, 1:0.015, 1:0.007 
and 1:0 respectively) and with tumor or peritumoral 
CD4+CD25+ Tregs in 1:1 ratio. Cells were cultured 
(5×103 cells/well) in U-bottom 96-well plates with RPMI 
medium (Thermo scientific, HyClone Laboratories, 
Inc) supplemented with 2-mM L-glutamine, 100 U/ml 
penicillin, 100 μg streptomycin, and 10% fetal bovine 
serum. Cells were stimulated for 5 days in the presence 
of Dynabeads Human T-Activator CD3/CD28 (Gibco 
by Life Technologies). As additional control, Teff cells 
were cultured alone with and without the Dynabeads 
Human T-Activator CD3/CD28 and Tregs were cultured 
alone with Dynabeads Human T-Activator CD3/CD28. 
The suppressive activity of Tregs was assessed by 
evaluating the CFSE-labeled Teff cells by FACS analysis. 
Furthermore, Tregs were pretreated for 30’ at 37°C in 5% 
CO2 with 10 μM of Peptide R29, a modified Peptide R 
(also known as compound 10) a new class of CXCR4 
antagonists [17, 18], 10 μM of AMD3100 (Sigma-Aldrich) 
a selective CXCR4 antagonist or 20 μg/mL of anti PD-1 
before coculture with Teff cells. As control, activated Teff 
cells were cultured in the presence of CXCR4 antagonists.
Methylation studies: genomic DNA isolation, 
bisulfite conversion, and qPCR
Genomic DNA (gDNA) of peripheral Tregs isolated 
from 4 HD and 5 RCC patients was obtained by using 
a traditional phenol/chloroform extraction method 
with minor modifications. Bisulfite treatment of 500 ng 
genomic DNA was performed by using the EZ DNA 
Methylation™ Kit (ZYMO Research) according to the 
manufacturer’s instructions. qPCR was prepared by using 
SensiMix SYBR Kit (Bioline, London) and performed by 
LightCycler® 480 System (Roche Diagnostics). Primers 
for methylation and demethylation-specific FOXP3-
TSDR and computing of the demethylation rate (DMR) 
of FOXP3-TSDR were previously described [12]. Briefly, 
we used the following formula: 100/[1 + 2(CtTG- CtCG)] 
× 100%, where CtTG represents the cycle threshold (Ct) 
achieved with TG (demethylated) primers and CtCG 
represents the Ct achieved with CG (methylated) primers. 
For female patients, this rate was corrected by a factor of 
2 because one of the two TSDR alleles is methylated as a 
result of X inactivation.
Cytokine assay
IFN-γ and TGF-β1 were measured by ELISA 
assay on the culture supernatant collected on day 5 
from suppression experiments. In particular, cytokine 
concentration was assessed by Human IFN-gamma Instant 
ELISA (Bender MedSystems) and Human TGF-β1 ELISA 
kit (Boster Biological Technology Co). Samples were 
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acquired by LB 940 Multimode Reader Mithras (Berthold 
Technologies).
Viability assays
Isolated CD4+CD25+ T cells were incubated for 30’ 
at 37°C in 5% CO2 with or without 10 μM of Peptide R29. 
After 30’ the cells were washed and then stained with 
Fitc-anti-CD25, APC-Cy7-anti-CD4 (BD Bioscience) 
and 7-amino-actinomycin D (7-AAD) (BioLegend) and 
analyzed by flow cytometer.
Real-time PCR
RNA was extracted from frozen RCC tumor and 
corresponding peritumoral tissues using the RNeasy Mini 
kit (Qiagen), according to manufacturer’s instructions. 
The primer sequences were designed using Primer3: 
GUSB, sense 5’-AGCCAGTTCCTCATCAATGG-3’; 
antisense 5’-GGTAGTGGCTGGTACGGAAA-3’; IL10, 
sense 5’-TGGGGGAGAACCTGAAGA -3’; antisense 
5’-TGGCTTTGTAGATGCCTTTC-3’; TGFB1, sense 
5’- ATGGGGGCTGTATTTAAGGA-3’; antisense 
5’-AGGCAGAGAGGGAGAGAGA -3’. Samples 
were run in triplicate, and their relative expression was 
calculated in the following formula using GUSB as 
endogenous control: 2-ΔΔCt.
Statistical analysis
Data were presented as mean values ± s.d.; statistical 
analyses were done using the paired and unpaired two-
tailed Student’s t- test. P-values less than 0.05 were 
considered statistically significant (*P< 0.05; **P< 0.01; 
***P< 0.001).
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